- VRTX +1.36%
Search results
Vertex Pharmaceuticals | Home. At Vertex, we invest in scientific innovation to create transformative medicines for people with serious diseases. Read More. News. Jennifer Schneider elected to Vertex Board of Directors. Learn more. Vertex reports first quarter 2024 financial results. Learn More.
- 456.95Add to watchlist+6.15 (+1.36%)At close:4:00 PM EDTFri. May 24, 2024456.50 -0.45 (-0.10%)After hrs:7:59 PM EDTFri. May 24, 2024Nasdaq Real Time Price (USD) · Market closed
- Open451.90High457.66Low449.42
- Mkt Cap117.92BP/E (TTM)29.67Div & YieldN/A & N/A
- Prev. Close450.8052 Wk. Low320.0152 Wk. High457.66
What analysts are sayingTop storiesNew Pain Drug Could Be Big For Vertex Stock As Shares Score BreakoutInvestor's Business Daily · 7 hours agoVertex (VRTX) Outperforms Industry on Rapid Pipeline ProgressYahoo Finance · 3 days ago- VRTX +1.36%
Insider Sale: CEO & President Reshma Kewalramani Sells 15,202 Shares of Vertex ...Yahoo Finance · 2 days agoRelated stocks
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
In 2023, we ranked #12 in the Mega Employer category. Vertex Pharmaceuticals strikes at the core of serious diseases to change people's lives – learn about our mission, values and recognition.
Dec 8, 2023 · BOSTON & ZUG, Switzerland -- (BUSINESS WIRE)--Dec. 8, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 genome-edited cell therapy, for the treatment of ...
Jan 30, 2024 · BOSTON -- (BUSINESS WIRE)--Jan. 30, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 3 program for the selective NaV1.8 inhibitor, VX-548, in the treatment of moderate-to-severe acute pain.
Dec 13, 2023 · BOSTON -- (BUSINESS WIRE)--Dec. 13, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with painful diabetic peripheral neuropathy (DPN).
BOSTON -- (BUSINESS WIRE)--Oct. 3, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented longer-term data on patients dosed in Parts A and B of its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy in people with type 1 diabetes (T1D) with impaired hypoglycemic a...